INTRODUCTION

Glaucoma is a leading cause of blindness in
Latin America and worldwide [1] . Globally, nearly 80 million people are projected to be diagnosed with glaucoma in 2020, more than 8 million of whom are expected to be from Latin America [1] . Elevated intraocular pressure (IOP) is a major risk factor for primary open-angle glaucoma [2] ; the primary treatment approach to slow progression of glaucoma and ocular hypertension is reducing IOP [3] . Several topical IOP-lowering medications exist; these include medications that decrease aqueous humor production and increase aqueous humor outflow (e.g., carbonic anhydrase inhibitors, bblockers, a-agonists) [3] . Treatment with a single topical agent is often insufficient to control IOP, and many patients require an additional IOP-lowering agent to achieve their targets [3, 4] . Concomitant use of multiple ocular hypotensive agents may be inconvenient and has been associated with increased risk of drug washout [5] , decreased adherence and persistence [6, 7] , increased exposure to preservatives and risk of preservative-related ocular surface disease [8, 9] , and potentially higher treatment costs [10] . has shown efficacy greater than brimonidine or timolol monotherapy alone in patients with glaucoma or ocular hypertension [14] .
The objective of this study was to assess the efficacy and tolerability of transitioning to BRINZ/TIM-FC from prior BRIM/TIM-FC in Latin American patients with open-angle glaucoma or ocular hypertension.
METHODS
Study Design
This 
Safety Outcomes
Safety was assessed by monitoring adverse event (AE) reports. Ocular signs (evaluated by slitlamp biomicroscopy) and BCVA were evaluated for each eye at all study visits.
Statistical Analysis
If only one eye was eligible for inclusion and treatment, this eye was selected for the efficacy analysis; if both eyes were eligible, the worse eye (i.e., the eye with the higher IOP at baseline) was selected. If both eyes had equal IOP at baseline, the right eye was selected. Efficacy outcomes were analyzed in the intent-to-treat 
RESULTS
Patients
Fifty patients were screened and enrolled in the study and included in the safety population.
Open anterior chamber angle was confirmed for all patients. Mean ± SD patient age was 66.7 ± 11.5 years (range 29-87 years); 61.2% of patients were female, and 89.8% were Hispanic (Table 1) . Three patients discontinued because of AEs (keratitis, bacterial conjunctivitis, and eye irritation); one patient discontinued between baseline and week 4 and was excluded from the ITT analysis (n = 49), and two patients discontinued between weeks 4 and 8.
Efficacy
Efficacy data were similar in the ITT and perprotocol populations; results for the ITT population are presented. At baseline (on BRIM/TIM-FC; n = 49), mean ± SD IOP was 21.2 ± 2.5 mmHg. Mean ± SD absolute IOP reduction from baseline to week 8 (on BRINZ/ TIM-FC; n = 47) was -3.6 ± 3.0 mmHg (P\0.0001); mean ± SD percent IOP change from baseline to week 8 was -17.1 ± 13.7%.
Mean IOP decreased from baseline to week 4 (n = 49) and was maintained through week 8 ( Fig. 1) . At week 8, 55.3% of patients (n = 26/47) achieved the target IOP of B18 mmHg.
The proportion of patients reporting the symptoms described in the ocular symptom survey decreased from baseline to week 8, except for crusting around the eyes, which increased from 12.2% (n = 6/49) to 27.7% (n = 13/47; Table 2 ). Dry eyes; excessive tearing; and itching of the eyes, eyelids, or the area around the eyes were significantly improved from baseline to week 8 (all P\0.05; Table 2 ).
Most patients (89.4%, n = 42/47) preferred BRINZ/TIM-FC to BRIM/TIM-FC (P\0.0001).
Investigators preferred BRINZ/TIM-FC to BRIM/TIM-FC for nearly all patients (95.7%, n = 45/47; P\0.0001).
All but 1 patient (97.9%, n = 46/47) were very confident that they would adhere to their preferred glaucoma medication if it was prescribed by their doctor, compared with 61.7% (n = 29/47) who were very confident that they would adhere to their non-preferred medication if it was prescribed (Table 3 ). In total, 87.2% (n = 41/47) of patients were very confident they would use a prescribed medication if it did not make their eyes burn or sting, whereas 59.6% (n = 28/47) of patients were very confident that they would use a prescribed medication if it did cause such symptoms (Table 3) . BMI Body mass index, BRINZ/TIM-FC fixedcombination brinzolamide 1%/timolol 0.5% a Two diagnoses were recorded for some patients, causing the total number of diagnoses to exceed 49 b Recorded for each patient who had a single glaucoma entry for both eyes; type of glaucoma was not allowed to be specified for each eye. Two patients presented with pseudoexfoliation glaucoma and were included as nonspecified glaucoma; one patient had open-angle glaucoma in both eyes but was assigned to the non-specified glaucoma group because of a coding error
Safety
A total of 13 AEs were reported for 10 patients (Table 4) No substantial changes in ocular signs or BCVA were observed throughout the study, and the safety profile of BRINZ/TIM-FC was similar to previous reports [12, 13] . consistently maintained IOP levels B18 mmHg over 6 years compared with patients who had higher IOP levels [16] . In the Canadian Glaucoma Study, among 249 patients with open-angle glaucoma, those with mean IOP [17 mmHg had significantly higher cumulative progression compared with those with mean IOP \15 mmHg [17] ; this study also found that the risk of progression increased by 19% for every 1-mmHg increase in mean IOP [17] .
Similarly, the Early Manifest Glaucoma Trial demonstrated that the risk of progression decreased by *10% for every 1-mmHg decrease in IOP from baseline at follow-up visits [18] . This finding was further supported by the Canadian Glaucoma Study follow-up [20] .
The difference in IOP with BRINZ/TIM-FC versus BRIM/TIM-FC in the current study was of greater magnitude than was previously reported [20] ; however, the current study did not control for potential non-compliance with prior BRIM/TIM-FC.
The safety and tolerability profiles of BRINZ/ TIM-FC and BRIM/TIM-FC in the current study were similar to previous reports. In a large, multicenter, observational study of more than 14,000 patients throughout Germany who transitioned to BRINZ/TIM-FC from prior IOPlowering medications, nearly 90% of patients judged the tolerability of BRINZ/TIM-FC positively [13] . A total of 75.9% of evaluable patients reported a preference for BRINZ/TIM-FC compared with 8.6% who reported a preference for their previous therapy [13] . Of 
